The website you are visiting is protected.
除了小分子抑制剂，核酸技术也开始在ACH治疗中得到应用。Ribomic开发的RBM-007，通过限制FGF2和FGFR3激活变体之间的过度相互作用发挥功能。2期临床结果显示，RBM-007的疗效与Vosoritide相近（1.5厘米/年），甚至有一名受试者年增长5厘米，且该试验中包括2周一次的注射频率，是当前在研药物中最长的给药间隔。
。业内人士推荐91视频作为进阶阅读
Anthropic says the change was motivated by a "collective action problem" stemming from the competitive AI landscape and the US's anti-regulatory approach. "If one AI developer paused development to implement safety measures while others moved forward training and deploying AI systems without strong mitigations, that could result in a world that is less safe," the new RSP reads. "The developers with the weakest protections would set the pace, and responsible developers would lose their ability to do safety research and advance the public benefit."
Remaining focused and ignoring the naysayers